Compare Silicon Motion Technology Corporation American Depositary Shares (SIMO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Silicon Motion Technology Corporation American Depositary Shares vs Vertex Pharmaceuticals Incorporated — how do they compare? Silicon Motion Technology Corporation American Depositary Shares trades at $221 (market cap $8.36B), while Vertex Pharmaceuticals Incorporated trades at $504.87 (market cap $122.98B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 14.7× Silicon Motion Technology Corporation American Depositary Shares's market cap, and Silicon Motion Technology Corporation American Depositary Shares pays a 0.81% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Silicon Motion Technology Corporation American Depositary Shares for 0 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SIMO | VRTX | |
|---|---|---|
Market Cap | $8.36B | $122.98B |
Volume | 663,682 | 1,155,743 |
Sector | Technology | Health |
52-Week High | $336.90 | $557.96 |
52-Week Low | $80.16 | $407.90 |
Typical Hold Time | 0 Days | 120 Days |
Enterprise Value | $8.35B | $117.11B |
Dividend Yield | 0.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Silicon Motion (SIMO) trades at $246.63, down 0.13% on the day, with technical indicators showing neutral signals. The company demonstrates strong fundamentals with Q2 2026 EPS beating expectations at $2.43 versus $2.13, and revenue growth projected to reach $1.3B in 2026. Analyst sentiment remains overwhelmingly positive with 81% buy ratings and a consensus price target of $356.25, representing 44% upside potential from current levels.
The outlook for SIMO appears favorable given accelerating enterprise storage demand and AI infrastructure expansion. Key risks include semiconductor cycle volatility and competitive pressures in NAND controllers. With robust profitability metrics including 31.6% ROE and expanding margins, the stock offers growth exposure to the AI storage market, though investors should monitor execution on Q3 2026 earnings expectations of $3.3 EPS.
Vertex Pharmaceuticals (VRTX) trades at $498.50, down 1.68% amid mixed technical signals. The stock shows strong fundamentals with $12B revenue, 35% net margins, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Technical indicators show bearish momentum with support at $496 and resistance at $512.
Outlook remains positive with 86% analyst buy ratings and $573.50 price target. Key risks include clinical trial outcomes and competitive pressures. The company's expanding pipeline and profitability provide upside potential, though near-term volatility may persist around key technical levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Silicon Motion Technology Corporation American Depositary Shares
Silicon Motion Technology Corporation designs and develops NAND flash controllers for solid-state storage, with flagship SSD, eMMC, and UFS controller products, including its Ferri-branded automotive and industrial storage solutions, used by OEMs and NAND flash makers worldwide.
Read more on SIMO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
